Kesselring will work with the MAPS Professional Development Committee to assist with the creation of courses supporting 7 Medical Affairs competency certification tracks identified in the MAPS 5-year strategic plan.
This white paper addresses insights challenges in Strategy, Data Generation, and Analysis/Reporting – arming Medical Affairs teams with the tools and opportunity to build strategies that preempt these challenges.
This white paper by the MAPS Field Medical FAWG details strategies for optimizing your Field Medical team for the OmniChannel World
This white paper by the MAPS Medical Communications FAWG details strategies for using modular content to increase the efficiency and accuracy of medical and scientific content to enable omnichannel engagement strategy.
The growth of Real-World Evidence (RWE) from sources including patient registries, claims data, electronic medical records, digital health technologies and more has powered the ability of Medical Affairs to drive patient outcomes. Here, the MAPS Executive Consortium describes how.
MAPS is pleased to share our 2023 Medical Metrics Benchmarking Report, based on findings from 51 leading organizations representing the Pharmaceutical, Biotech, and Medical and Diagnostic Device sectors.
MAPS announces the election of Dr. Danie du Plessis as Chair of the MAPS Board of Directors. Du Plessis is currently Executive Vice-President (EVP) & Head of Medical Affairs at Kyowa Kirin International and is a senior pharmaceutical executive with 30 years’ experience.
This White Paper draws on the expertise of 10 senior Medical Affairs leaders across diverse global organizations to describe the role of Medical Affairs in ensuring the MedTech industry meets the challenges of high-quality evidence, objective measures, changes in the healthcare landscape, and more.
This White Paper provides a foundational understanding of insights management, including the definition and value of insights, processes and technologies for insights management, and key challenges in implementation.
This article outlines the aspects of Medical Affairs strategy and launch excellence specific to supporting the development and launch of treatments targeting rare diseases, providing a roadmap for MA teams and organizations undertaking this planning.